The Stanford team is currently conducting trials of targeted agents in gastroesophageal, colorectal, pancreatic, GIST, and neuroendocrine tumors.
For patients with early stage pancreatic cancer, a Phase III trial is testing a novel vaccine in combination with standard chemotherapy or chemoradiation.
Recent GI cancer research breakthroughs
Stanford doctors conducted several of the key trials that led to the widespread use of targeted therapies for GI cancers, including angiogenesis inhibitors for colorectal, neuroendocrine, and hepatocellular cancer and epidermal growth factor receptor (EGFR) inhibitors that are now routinely used in colorectal cancers.
The Stanford Gastrointestinal (GI) Cancer Program always has new clinical trials beginning. Before beginning treatment, ask your doctor about any clinical trials you should consider. Learn more about clinical trials for cancer patients.
Clinical trial eligibility flowcharts
Eligibility flowcharts map clinical trials to specific types of cancers to determine if a participant is eligible for the particular clinical trial. View all gastrointestinal cancer eligibility flowcharts at the Stanford Cancer Institute.